ATS 2020 Advance Program

3:20 Under Recognized Etiologies of Exacerbations S.P. Bhatt, MD, MSPH, Birmingham, AL 3:35 Biomarkers for Acute Exacerbations: Challenges and Promise D.D. Sin, MD, Vancouver, Canada 3:50 Treatment of Exacerbations: Do They Need More Nuance? F.J. Martinez, MD, MS, New York, NY 4:05 Panel Discussion BASIC • CLINICAL • TRANSLATIONAL CLINICAL TOPICS IN PULMONARY MEDICINE C83 THE ROLE OF LUNG MICROBIOME IN INTERSTITIAL LUNG DISEASES: STATE OF THE ART AND FUTURE DIRECTIONS Assemblies on Clinical Problems; Allergy, Immunology and Inflammation; Environmental, Occupational and Population Health; Pulmonary Infections and Tuberculosis 2:15 p.m. - 4:15 p.m. Target Audience Medical practitioners, basic scientists, trainees, students, postdoc fellows, junior faculty involved in chronic lung injury research and treatment, including ILDs, interested in hearing advances in rare lung disease research like IPF. Objectives At the conclusion of this session, the participant will be able to: • learn new findings about the interactions of innate immunity and the microbiome in interstitial lung disease; • Improve understanding of how lung microbiome influences ILDs pathogenesis; • begin to understand how host-microbiome interaction can be used as therapeutic target in ILDs. This symposium is going to explore in depth the role of lung microbiome studies in the field of Interstitial Lung Diseases. It will provide insights about the state of the art, analyzing also the actual limitations of these studies, and it will give a glimpse into the future directions that we will be able to travel in the next future. Particular importance is given to the crosstalk between lung and GI tract microbiome, the pathogenic processes leading to pulmonary fibrosis and the impact of lung microbiome studies on future therapeutic approaches for these rare diseases. Chairing: J.J. Swigris, MS, DO, Denver, CO L. Richeldi, PhD, MD, Rome, Italy B.B. Moore, PhD, ATSF, Ann Arbor, MI P.M. Leone, MD, Rome, Italy 2:15 Host-Microbiome Interaction in Chronic Lung Diseases: A Historic Insight M.L. Salisbury, MD, Nashville, TN 2:35 Crosstalk Between Gastro-Intestinal Tract and Lung Microbiome: Does It Impact on Lung Fibrosis? D.N. O’Dwyer, BM BCH, BMedSci, PhD, Ann Arbor, MI 2:55 Focus on GERD and Lung Fibrosis: Is the Lung Microbiome the Missing Chain Link? J.J. Swigris, MS, DO, Denver, CO 3:15 Lung Microbiome in IPF and its Acute Exacerbations P.L. Molyneaux, MBBS, BS(Hons), London, United Kingdom 3:35 Lung Microbiome in Interstitial Lung Diseases Other Than IPF L.N. Segal, MD, New York, NY 3:55 How Lung Microbiome Studies May Impact on Future ILDs Therapies? L. Richeldi, PhD, MD, Rome, Italy CLINICAL CRITICAL CARE TRACK C84 HAS THE PENDULUM SWUNG TOO FAR? EVALUATING CURRENT PRACTICES IN CRITICAL CARE Assemblies on Critical Care; Behavioral and Health Services Research ATS 2020 • Philadelphia, PA TUESDAY • MAY 19 115